Proton Magnetic Resonance Spectroscopy Measurement of Brain Glutamate Levels in Premenstrual Dysphoric Disorder
- Buckley, P. MD
Background.
Women who suffer from premenstrual dysphoric disorder (PMDD) classically display depressive and anxiety symptoms in the premenstrum. Preclinical and clinical studies have suggested a role of glutamate in anxiety and depression. This investigation aims at demonstrating fluctuations of glutamate across the menstrual cycle in the medial prefrontal cortex of women who suffer from PMDD and healthy control subjects (HCs).
Methods.
Twelve PMDD women and 13 HCs were randomized to two single-voxel 3 Tesla proton magnetic resonance spectroscopy examinations of the medial prefrontal cortex during the follicular phase and the luteal phase.
Results.
A phase effect was observed; the levels of glutamate/creatine plus phosphocreatine (Cr) were significantly lower during the luteal phase compared with the follicular phase. However, no statistically significant diagnosis or phase × diagnosis effects were found.
Conclusions.
The optimized stimulated echo acquisition mode (STEAM) pulse timings selected in this study (echo time [TE], mixing time [TM] = 240, 27 msec) allow us to interpret our results as the first report of alterations of brain glutamate levels across the menstrual cycle. Hormonal fluctuations associated with the menstrual cycle likely contribute to these glutamate level variations. Although PMDD women undergo a similar decrease in glutamate during the luteal phase as the HCs, PMDD women may display an increased behavioral sensitivity to those phase-related alterations. These menstrual cycle-related variations of glutamate levels may also contribute to the influence of the phases of the menstrual cycle in other neuropsychiatric disorders (Fig 2).
FIGURE 2.
—Glutamate/creatine plus phosphocreatine (glutamate/Cr) levels ± standard deviation in the medial prefrontal cortex in women with premenstrual dysphoric disorder (n = 12) and healthy control subjects (n = 13) across the menstrual cycle. A phase effect was observed [F(1,21) = 7.115, p = .014]. Cr, creatine plus phosphocreatine; FP, follicular phase; HC, healthy control subjects; LP, luteal phase; MPFC, medial prefrontal cortex; PMDD, premenstrual dysphoric disorder. (Reprinted from Batra NA, Seres-Mailo J, Hanstock C, et al. Proton magnetic resonance spectroscopy measurement of brain glutamate levels in premenstrual dysphoric disorder. Biol Psychiatry. 2008;63:1178-1184, with permission from the Society of Biological Psychiatry.)